1. Home
  2. OPT vs MYI Comparison

OPT vs MYI Comparison

Compare OPT & MYI Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.

  • Machine Learning Prediction
  • ML Decision
  • OPT
  • MYI
  • Stock Information
  • Founded
  • OPT 1984
  • MYI 1992
  • Country
  • OPT Australia
  • MYI United States
  • Employees
  • OPT N/A
  • MYI N/A
  • Industry
  • OPT Biotechnology: Biological Products (No Diagnostic Substances)
  • MYI Investment Bankers/Brokers/Service
  • Sector
  • OPT Health Care
  • MYI Finance
  • Exchange
  • OPT Nasdaq
  • MYI Nasdaq
  • Market Cap
  • OPT 767.9M
  • MYI 767.7M
  • IPO Year
  • OPT 2020
  • MYI N/A
  • Fundamental
  • Price
  • OPT $3.22
  • MYI $11.06
  • Analyst Decision
  • OPT Strong Buy
  • MYI
  • Analyst Count
  • OPT 1
  • MYI 0
  • Target Price
  • OPT $12.00
  • MYI N/A
  • AVG Volume (30 Days)
  • OPT 13.0K
  • MYI 256.7K
  • Earning Date
  • OPT 08-30-2024
  • MYI 01-01-0001
  • Dividend Yield
  • OPT N/A
  • MYI 4.81%
  • EPS Growth
  • OPT N/A
  • MYI N/A
  • EPS
  • OPT N/A
  • MYI N/A
  • Revenue
  • OPT $261,859.00
  • MYI N/A
  • Revenue This Year
  • OPT N/A
  • MYI N/A
  • Revenue Next Year
  • OPT $46,864.64
  • MYI N/A
  • P/E Ratio
  • OPT N/A
  • MYI N/A
  • Revenue Growth
  • OPT N/A
  • MYI N/A
  • 52 Week Low
  • OPT $1.79
  • MYI $9.32
  • 52 Week High
  • OPT $5.45
  • MYI $11.70
  • Technical
  • Relative Strength Index (RSI)
  • OPT 40.67
  • MYI 31.66
  • Support Level
  • OPT $3.15
  • MYI $11.43
  • Resistance Level
  • OPT $3.78
  • MYI $11.61
  • Average True Range (ATR)
  • OPT 0.18
  • MYI 0.12
  • MACD
  • OPT -0.00
  • MYI -0.04
  • Stochastic Oscillator
  • OPT 25.91
  • MYI 1.72

About OPT Opthea Limited

Opthea Ltd operates in one industry being the medical technology and healthcare. It is focused on developing biological therapeutics for eye diseases. The company is developing a novel biologic therapy, OPT-302, for the treatment of eye diseases. Its products are based on the intellectual property portfolio covering Vascular Endothelial Growth Factors C and D and R3 targets. Opthea's development activities are based on an intellectual property portfolio covering key targets Vascular Endothelial Growth Factors VEGF-C, VEGF-D and VEGF Receptor-3 for the treatment of diseases associated with blood and lymphatic vessel growth, as well as vascular leakage. The company geographically operates Australia and United States.

About MYI Blackrock MuniYield Quality Fund III Inc

BLACKROCK MUNIYIELD QUALITY FUND III, INC. is a investment management company. Its investment objective is to provide shareholders with a high level of current income exempt from U.S. federal income taxes as is consistent with its investment policies and prudent investment management. The company invests in various sectors such as Transportation; Utilities; Health; Education; Tobacco and others.

Share on Social Networks: